The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs raises penumbra price target to 320 maintaining buy rating
UBS analyst Priya Sachdeva raised Penumbra's stock price target to $320 from $305, maintaining a Buy rating following strong fourth-quarter results and 2025 guidance. The company reported EPS of $0.97 and revenue of $321.3 million, exceeding expectations, while projecting 12-14% revenue growth for the upcoming fiscal year. Analysts highlight significant growth in Penumbra's U.S. thrombectomy business and its strategic focus on expanding its CAVT portfolio to capture more market share.
ubs raises penumbra price target to 320 maintaining buy recommendation
UBS analyst Priya Sachdeva raised Penumbra's price target from $305 to $320, maintaining a Buy rating after the company reported strong fourth-quarter results and 2025 guidance. With a gross margin of 63.2% and a liquidity ratio of 6.01, Penumbra is positioned for steady growth, particularly through its CAVT portfolio in medical procedures. Canaccord Genuity and BTIG also increased their price targets, reflecting confidence in the company's profitability and market expansion plans.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.